+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
Healthy Volunteers
ID06033703

Evaluation of Topical Netarsudil for Preventing Proliferative Vitreoretinopathy in Retinal Detachment Patients Undergoing Surgery

Led by Massachusetts Eye and Ear Infirmary · Updated on 2026-10-16

48

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the pharmacokinetics and safety of topical Netarsudil in patients with retinal detachment, focusing on preventing the formation of tractional membranes. This open-label, randomized phase III trial includes patients with primary rhegmatogenous detachments and those with proliferative vitreoretinopathy or retinal detachment due to open globe injury. The study aims to understand how Netarsudil behaves in the eyes posterior segment and assess safety during pre- and post-operative periods, also exploring early signs of its effectiveness in preventing membrane formation. Participants will receive topical Netarsudil ophthalmic solution 0.02% once daily, starting from diagnosis of retinal detachment through 16 weeks after surgery. The study includes four groups based on lens status phakic or pseudophakic and type of retinal detachment primary rhegmatogenous or secondary due to proliferative vitreoretinopathy or trauma. All patients undergo vitrectomy or vitrectomy with scleral buckle as part of their surgical repair. During the study, participants will be monitored through scheduled visits on days 1, 7, 28, 84, and 168 after surgery. Researchers will measure Netarsudil concentration in the vitreous, track serious adverse events, assess visual acuity, examine the macula using spectral domain optical coherence tomography, and record any additional operations within three months. Safety and efficacy signs will be evaluated with regular follow-ups lasting about 16 weeks post-operation.

CONDITIONS

Brief Title

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

Research Team

L

Leo Kim, MD, PhD

C

Center for Clinical Research Operations (CCRO)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here